{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:27:01Z","timestamp":1790040421030,"version":"4.0.1"},"reference-count":48,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Genetic factors, inflammatory cytokines such as interleukin (IL)\u20106 and tumor necrosis factor\u2010\u03b1 (TNF\u2010\u03b1), and uremic substances such as 3\u2010carboxy\u20104\u2010methyl\u20105\u2010propyl\u20102\u2010furanpropanoic acid (CMPF) have been reported to affect organic anion transporting polypeptide (OATP)1B1 transport activity. However, the relationship between OATP1B1 transport activity and these factors in patients with cancer cachexia has not been reported. This study aimed to identify the factors contributing to individual differences in OATP1B1 transport activity in patients with cancer cachexia, using coproporphyrin\u2010I (CP\u2010I) as an endogenous biomarker of OATP1B1 transport activity. The study recruited 114 patients with cancer cachexia who satisfied the selection criteria. The subjects were classified into pre\u2010cachexia, cachexia, and refractory cachexia. Median [interquartile range] plasma CP\u2010I level was higher in patients with pre\u2010cachexia (0.91 [0.67\u20131.12] ng\/mL) compared with the data in the general population reported previously and tended to be higher in patients with refractory cachexia (1.06 [0.78\u20131.64] ng\/mL) than in those with cachexia (0.87 [0.62\u20131.07] ng\/mL), suggesting that OATP1B1 transport activity may decrease with the progression of cancer cachexia. Plasma CP\u2010I correlated positively with IL\u20106 and TNF\u2010\u03b1 concentrations but did not correlate with OATP1B1 polymorphisms or CMPF concentration, which have been reported to reduce transport activity. Multiple regression analysis using the forced entry method identified refractory cachexia as a significant factor independently affecting plasma CP\u2010I concentration. These findings suggest that the reduction in OATP1B1 transport activity in patients with cancer cachexia may be attributed to inflammatory cytokines or some other factors that are elevated by cancer cachexia progression, rather than OATP1B1 polymorphisms and CMPF.<\/jats:p>","DOI":"10.1002\/cpt.3649","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T03:04:51Z","timestamp":1742180691000},"page":"128-137","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Cancer Cachexia Progression on OATP1B1 Transport Activity: Quantitative Analysis Using Coproporphyrin\u2010I as an Endogenous Biomarker"],"prefix":"10.1002","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-2142","authenticated-orcid":false,"given":"Takahiro","family":"Sumimoto","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Oita University Hospital  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-7971","authenticated-orcid":false,"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Oita University Hospital  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7092-4618","authenticated-orcid":false,"given":"Yosuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Medication Use Analysis and Clinical Research Meiji Pharmaceutical University  Kiyose Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Negami","sequence":"additional","affiliation":[{"name":"Department of Medication Use Analysis and Clinical Research Meiji Pharmaceutical University  Kiyose Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3762-6731","authenticated-orcid":false,"given":"Yoshio","family":"Sueshige","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Oita University Hospital  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Medication Use Analysis and Clinical Research Meiji Pharmaceutical University  Kiyose Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-1711","authenticated-orcid":false,"given":"Ken","family":"Shiraiwa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Oita University Hospital  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology Oita University Faculty of Medicine  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology Oita University Faculty of Medicine  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-362X","authenticated-orcid":false,"given":"Ryosuke","family":"Tatsuta","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Oita University Hospital  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Otsu","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology Oita University Faculty of Medicine  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-5878","authenticated-orcid":false,"given":"Masao","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology Oita University Faculty of Medicine  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Medication Use Analysis and Clinical Research Meiji Pharmaceutical University  Kiyose Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-9356","authenticated-orcid":false,"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Oita University Hospital  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13216"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16188"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3829"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.105"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.06.011"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.276733.115"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12652"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2013.07.016"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu085"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00430.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100038"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1266-x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.128"},{"key":"e_1_2_10_15_1","unstructured":"Ono Pharmaceutical Co. L.The drug interview form of Anamorelin Hydrochloride (ADLUMIZ\u00ae)<https:\/\/www.ono\u2010oncology.jp\/system\/files\/2024\u201011\/ADM_IF_1.pdf>. (2023). Accessed 13 December 2024."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.001909"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1823"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200411000-00006"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2429"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M103792200"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.032268"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1695"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-013-1153-x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.023630"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1216"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.721"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1599"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113202"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12889"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12348"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.02.344"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000343822"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01566-8"},{"key":"e_1_2_10_34_1","first-page":"1001","article-title":"Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients","volume":"85","author":"Onodera T.","year":"1984","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"e_1_2_10_35_1","unstructured":"Center for Drug Evaluation and Research US Food and Drug Administration.Guidance for industry: bioanalytical method validation<https:\/\/www.fda.gov\/media\/70858\/download>. (2018). Accessed 11 October 2024."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13629"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15640"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2375"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.002019"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1785-0"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-012-6636-9"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2010.05.006"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.983"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12996"},{"key":"e_1_2_10_45_1","first-page":"258","article-title":"UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy","volume":"9","author":"Ando Y.","year":"2007","journal-title":"Curr. Opin. Mol. Ther."},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500072"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04314-1"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2829"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T07:16:36Z","timestamp":1754723796000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/cpt.3649"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3649","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"2024-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}